BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MS Patients on Oral Therapies Are More Optimistic About Their Disease, According to Kantar Health Survey


4/3/2013 10:03:02 AM

NEW YORK, April 3, 2013—Multiple sclerosis patients who are taking oral disease-modifying drugs (DMD) are more optimistic about their future expectations for their disease than patients who are taking non-oral DMDs, according to new research from Kantar Health, a leading global healthcare advisory firm.

More than 950 MS patients were asked to predict whether they expected their disease to improve, worsen or be the same in a year. Among patients taking oral DMDs, 34 percent expect their disease to be better and 49 percent expect their disease to worsen, compared with 16 percent of patients taking non-oral DMDs expecting their disease to improve and 62 percent expecting it to worsen.

Additionally, patients who take oral DMDs are more satisfied with their lives since starting their current treatment. Thirty-six percent of MS patients on oral DMDs are more satisfied with their lives since starting their current treatment, compared with 27 percent of patients taking non-oral DMD treatments.

About three in four of the DMD patients who plan to ask their physician to switch them to a specific brand say they will request an oral DMD. Still, many physicians seem hesitant to prescribe an oral DMD.

“Oral treatments for MS have been on the market for about two years, and we’re starting to see patients who have had a relapse in the past two years switching to the oral DMDs,” said Rose Lorenzo, director of research at Kantar Health. “While patients who have switched to oral DMDs are significantly more satisfied with their treatment, doctors are still wary about the lack of safety data and potential side effects. Both patients and physicians may be more open to oral treatments as additional data becomes available.”

About Kantar Health Syndicated Studies

The study’s results were drawn from the Multiple Sclerosis Syndicated Patient Study, a nationally representative, self-administered survey. Topics covered include the health status, attitudes, behaviors and patient-reported outcomes among adults diagnosed with MS. Kantar Health conducts syndicated studies in across several therapeutic areas in the U.S.

About Kantar Health

Kantar Health is a leading global healthcare advisory firm and trusted advisor to the world’s largest pharmaceutical, biotech, and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and marketing expertise to help clients launch products and differentiate their brands in the marketplace.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from pre-clinical development to launch, acting as catalysts to successful decision making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.

About Kantar Health

Kantar Health is a leading global healthcare advisory firm and trusted advisor to the world’s largest pharmaceutical, biotech, and medical device and diagnostic companies. It combines evidence-based research capabilities with deep scientific, therapeutic and clinical knowledge, commercial development know-how, and marketing expertise to help clients launch products and differentiate their brands in the marketplace.

Kantar Health deeply understands the influence of patients, payers and physicians, especially as they relate to the performance and payment of medicines and the delivery of healthcare services. Its 700+ healthcare industry specialists work across the product lifecycle, from pre-clinical development to launch, acting as catalysts to successful decision making in life sciences and helping clients prioritize their product development and portfolio activities, differentiate their brands and drive product success post-launch. For more information, please visit www.kantarhealth.com.



Read at BioSpace.com

 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES